CHRS Stock Analysis: Buy, Sell, or Hold?
CHRS - Coherus Oncology, Inc. Common Stock
$1.45
-0.02 (-1.36%)
▼
5d:
-13.17%
30d:
+2.11%
90d:
-15.2%
WAIT
LOW Confidence
Analysis Updated: Jul 14, 2026 12:00 AM ET
Earnings: Aug 06, 2026
21d
Get Alerted When CHRS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
2 traders called CHRS this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: CHRS is down 13.2% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: CHRS is down 13.2% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: CHRS is currently trading at $1.45, which is considered slightly high relative to its 30-day fair value range of $1.40 to $1.56.
Technical Outlook: Technically, CHRS is in a strong uptrend. Immediate support is located at $1.39, while resistance sits at $1.71.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $7.80 (+437.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CHRS is in a strong uptrend. Immediate support is located at $1.39, while resistance sits at $1.71.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $7.80 (+437.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$1.40 -
$1.56
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
66.8%
All Signals
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 437.9% below Wall St target ($7.80)
- WARNING: Recommendation downgraded due to -13.2% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$1.40 -
$1.56
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$1.39
Resistance Level
$1.71
Current Trend
Strong Uptrend
Technical data as of
Jul 10, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.42
Wall Street Target
$7.80
(+437.9%)
Revenue Growth (YoY)
62.0%
Earnings Growth (YoY)
-75.5%
Profit Margin
397.3%
Share & Embed Analysis
Last updated: July 14, 2026 10:18 PM ET
Data refreshes hourly during market hours. Next update: 11:18 PM
Data refreshes hourly during market hours. Next update: 11:18 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CHRS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$88 | 65 BUY |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1051 | 52 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$277 | 58 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$85 | 50 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$34 | 55 HOLD |
